"Global Glioblastoma Multiforme Therapeutics Market 2015-2019" Published

Fast Market Research announces the availability of Technavio's new report "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" on their comprehensive research portal.

Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.

Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options.

Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market.

Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.

Get More Details on this Report and a Full Table of Contents at Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Commenting on the report, an analyst from Technavio’s team said: "The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells."

According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market.

Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period.

The key players in the Global Glioblastoma Multiforme Therapeutics Market are Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd. And Merck & Co. Ltd.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014
- Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM
- Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014
- AGY Therapeutics, Inc. - Product Pipeline Review - 2014
- Global Biologic Therapeutics Market 2014-2018